Microbiota alterations in proline metabolism impact depression.


Journal

Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170

Informations de publication

Date de publication:
03 05 2022
Historique:
received: 06 05 2021
revised: 31 01 2022
accepted: 04 04 2022
entrez: 4 5 2022
pubmed: 5 5 2022
medline: 7 5 2022
Statut: ppublish

Résumé

The microbiota-gut-brain axis has emerged as a novel target in depression, a disorder with low treatment efficacy. However, the field is dominated by underpowered studies focusing on major depression not addressing microbiome functionality, compositional nature, or confounding factors. We applied a multi-omics approach combining pre-clinical models with three human cohorts including patients with mild depression. Microbial functions and metabolites converging onto glutamate/GABA metabolism, particularly proline, were linked to depression. High proline consumption was the dietary factor with the strongest impact on depression. Whole-brain dynamics revealed rich club network disruptions associated with depression and circulating proline. Proline supplementation in mice exacerbated depression along with microbial translocation. Human microbiota transplantation induced an emotionally impaired phenotype in mice and alterations in GABA-, proline-, and extracellular matrix-related prefrontal cortex genes. RNAi-mediated knockdown of proline and GABA transporters in Drosophila and mono-association with L. plantarum, a high GABA producer, conferred protection against depression-like states. Targeting the microbiome and dietary proline may open new windows for efficient depression treatment.

Identifiants

pubmed: 35508109
pii: S1550-4131(22)00128-0
doi: 10.1016/j.cmet.2022.04.001
pii:
doi:

Substances chimiques

gamma-Aminobutyric Acid 56-12-2
Proline 9DLQ4CIU6V

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-701.e10

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Jordi Mayneris-Perxachs (J)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain. Electronic address: jmayneris@idibgi.org.

Anna Castells-Nobau (A)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain.

María Arnoriaga-Rodríguez (M)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain; Department of Medical Sciences, School of Medicine, Girona, Spain.

Miquel Martin (M)

Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.

Lisset de la Vega-Correa (L)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain.

Cristina Zapata (C)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain.

Aurelijus Burokas (A)

Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Gerard Blasco (G)

Institute of Diagnostic Imaging (IDI)-Research Unit (IDIR), Parc Sanitari Pere Virgili, Barcelona, Spain; Medical Imaging, IDIBGI, Girona, Spain.

Clàudia Coll (C)

Girona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta Hospital, Girona, Spain.

Anira Escrichs (A)

Computational Neuroscience Group, Center for Brain and Cognition, Department of Information and Communication Technologies, Universitat Pompeu Fabra, Barcelona, Spain.

Carles Biarnés (C)

Institute of Diagnostic Imaging (IDI)-Research Unit (IDIR), Parc Sanitari Pere Virgili, Barcelona, Spain; Medical Imaging, IDIBGI, Girona, Spain; Department of Radiology (IDI), Dr. Josep Trueta Hospital, Girona, Spain.

José María Moreno-Navarrete (JM)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain; Department of Medical Sciences, School of Medicine, Girona, Spain.

Josep Puig (J)

Department of Medical Sciences, School of Medicine, Girona, Spain; Institute of Diagnostic Imaging (IDI)-Research Unit (IDIR), Parc Sanitari Pere Virgili, Barcelona, Spain; Medical Imaging, IDIBGI, Girona, Spain; Department of Radiology (IDI), Dr. Josep Trueta Hospital, Girona, Spain.

Josep Garre-Olmo (J)

Research Group on Aging, Disability, and Health, Girona Biomedical Research Institute (IdibGi), Girona, Spain; Serra-Hunter Fellow, Department of Nursing, University of Girona, Girona, Spain; Institut d'Assistència Sanitària, Girona, Spain.

Rafel Ramos (R)

Department of Medical Sciences, School of Medicine, Girona, Spain; Vascular Health Research Group of Girona (ISV-Girona), Jordi Gol Institute for Primary Care Research (Institut Universitari Recerca Atenció Primària Jordi Gol i Gorina-IDIAPJGol), Girona, Spain; IDIBGI, Dr. Josep Trueta Hospital, Girona, Spain.

Salvador Pedraza (S)

Department of Medical Sciences, School of Medicine, Girona, Spain; Medical Imaging, IDIBGI, Girona, Spain; Department of Radiology (IDI), Dr. Josep Trueta Hospital, Girona, Spain.

Ramón Brugada (R)

IDIBGI, Dr. Josep Trueta Hospital, Girona, Spain; Biomedical Research Networking Center for Cardiovascular Diseases (CIBER), Madrid, Spain.

Joan Carles Vilanova (JC)

Department of Radiology (IDI), Dr. Josep Trueta Hospital, Girona, Spain; IDIBGI, Dr. Josep Trueta Hospital, Girona, Spain.

Joaquín Serena (J)

IDIBGI, Dr. Josep Trueta Hospital, Girona, Spain; Girona Neurodegeneration and Neuroinflammation Group, IDIBGI, Girona, Spain.

Jordi Gich (J)

Department of Medical Sciences, School of Medicine, Girona, Spain; Girona Neurodegeneration and Neuroinflammation Group, IDIBGI, Girona, Spain.

Lluís Ramió-Torrentà (L)

Department of Medical Sciences, School of Medicine, Girona, Spain; Girona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta Hospital, Girona, Spain; Girona Neurodegeneration and Neuroinflammation Group, IDIBGI, Girona, Spain.

Vicente Pérez-Brocal (V)

Area of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of València Region (FISABIO-Public Health), València, Spain; Biomedical Research Networking Center for Epidemiology and Public Health (CIBEResp), Madrid, Spain.

Andrés Moya (A)

Area of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of València Region (FISABIO-Public Health), València, Spain; Biomedical Research Networking Center for Epidemiology and Public Health (CIBEResp), Madrid, Spain; Institute for Integrative Systems Biology (I2Sysbio), University of València and Spanish Research Council (CSIC), València, Spain.

Reinald Pamplona (R)

Metabolic Physiopathology Research Group, Experimental Medicine Department, Lleida University-Lleida Biochemical Research Institute (UdL-IRBLleida), Lleida, Spain.

Joaquim Sol (J)

Metabolic Physiopathology Research Group, Experimental Medicine Department, Lleida University-Lleida Biochemical Research Institute (UdL-IRBLleida), Lleida, Spain; Institut Català de la Salut, Atenció Primària, Lleida, Spain; Research Support Unit, Fundació Institut Universitari recerca l'Atenció Primària Salut Jordi Gol i Gorina (IDIAPJGol), Lleida, Spain.

Mariona Jové (M)

Metabolic Physiopathology Research Group, Experimental Medicine Department, Lleida University-Lleida Biochemical Research Institute (UdL-IRBLleida), Lleida, Spain.

Wifredo Ricart (W)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain; Department of Medical Sciences, School of Medicine, Girona, Spain.

Manuel Portero-Otin (M)

Metabolic Physiopathology Research Group, Experimental Medicine Department, Lleida University-Lleida Biochemical Research Institute (UdL-IRBLleida), Lleida, Spain.

Gustavo Deco (G)

Computational Neuroscience Group, Center for Brain and Cognition, Department of Information and Communication Technologies, Universitat Pompeu Fabra, Barcelona, Spain; Institucio Catalana de la Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Neuropsychology, Max Planck Institute for human Cognitive and Brain Sciences, Leipzig, Germany; Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.

Rafael Maldonado (R)

Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Electronic address: rafael.maldonado@upf.edu.

José Manuel Fernández-Real (JM)

Department of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Girona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Girona, Spain; Department of Medical Sciences, School of Medicine, Girona, Spain. Electronic address: jmfreal@idibgi.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH